Levodopa carbidopa intestinal gel (LCIG)

DRUG2 trials

Sponsors

AbbVie (prior sponsor, Abbott)

Conditions

Advanced Parkinson's Disease

Phase 3

Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects

CompletedNCT00357994

AbbVie (prior sponsor, Abbott)Advanced Parkinson's Disease

Start: 2009-01-31End: 2011-10-31Updated: 2015-01-16

Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects

CompletedNCT00660387

AbbVie (prior sponsor, Abbott)Advanced Parkinson's Disease

Start: 2009-12-31End: 2011-10-31Updated: 2015-01-16

Related Papers

The effect of functional status impairment on nursing home admission risk among patients with advanced Parkinson’s disease

Journal of Medical Economics2019-11-159 citations

Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study.

2013-12-20470 citations